Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + vitamin k1
- Development stage
- Preclinical
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Sorafenib + vitamin K1 is an experimental combination therapy investigated for its synergistic effects in treating various cancers, including hepatocellular carcinoma (HCC), pancreatic adenocarcinoma, and malignant glioma. Sorafenib is a multi-kinase inhibitor that targets the RAF/MEK/ERK signaling pathway, while vitamin K1 (phylloquinone) has been shown to enhance sorafenib's growth-inhibitory and pro-apoptotic effects. Preclinical studies indicate that this combination can achieve therapeutic efficacy at lower doses of sorafenib, potentially reducing the drug's systemic toxicity. The mechanism involves the simultaneous inhibition of the RAF/MEK/ERK pathway and the activation of the JNK/c-Jun/FasL apoptotic pathway.
- Other names
- sorafenib + phylloquinonesorafenib + VK1
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)RAF1 (c-Raf-1 (Y340D/Y341D))MET (Mesenchymal-epithelial transition factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on sorafenib + vitamin k1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + vitamin k1.